Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
Company Details
- Employees
- 14
- Address
- 700 Larkspur Landing Circle,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://aulosbio.com/
- HQ
- Larkspur, California
Aulos Bioscience Questions
Aulos Bioscience's website is https://aulosbio.com/
Aulos Bioscience's LinkedIn profile is https://www.linkedin.com/company/aulos-bioscience
Aulos Bioscience has
14 employees.
View email and phone details for 14
employees at Aulos Bioscience.
Aulos Bioscience's industry is
Biotechnology Research
Aulos Bioscience's top competitors are
Rayzebio,
Trexbio,
Tenaya Therapeutics,
Replicate Bioscience, Inc.,
Surrozen,
Ukko,
Alumis,
Ascidian Therapeutics,
Biolojic Design, Ltd.,
Marengo Therapeutics.
Aulos Bioscience's categories are Biotechnology Research
